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Abstract
Current therapies for motor symptoms of Parkinson’s disease (PD) are based on dopamine replacement. However,
the disease progression remains unaffected, because of continuous dopaminergic neuron loss. Since oxidative stress is
actively involved in neuronal death in PD, pharmacological targeting of the antioxidant machinery may have
therapeutic value. Here, we analyzed the relevance of the antioxidant phase II response mediated by the transcription
factor NF-E2-related factor 2 (Nrf2) on brain protection against the parkinsonian toxin methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). Intraperitoneal administration of the potent Nrf2 activator sulforaphane (SFN) increased
Nrf2 protein levels in the basal ganglia and led to upregulation of phase II antioxidant enzymes heme oxygenase-1
(HO-1) and NAD(P)H quinone oxidoreductase (NQO1). In wild-type mice, but not in Nrf2-knockout mice, SFN
protected against MPTP-induced death of nigral dopaminergic neurons. The neuroprotective effects were accom-
panied by a decrease in astrogliosis, microgliosis, and release of pro-inflammatory cytokines. These results provide
strong pharmacokinetic and biochemical evidence for activation of Nrf2 and phase II genes in the brain and also offer
a neuroprotective strategy that may have clinical relevance for PD therapy. Antioxid. Redox Signal. 14, 2347–2360.
Introduction
Oxidative stress derived from oxidative dopamine (DA)metabolism, mitochondrial dysfunction, or inflamma-
tion plays a critical role in the pathogenesis of both familiar
and sporadic forms of Parkinson’s disease (PD) (2, 14). Based
on this fact, we have determined in this study whether the
transcription factor NF-E2-related factor-2 (Nrf2), master
regulator of redox homeostasis, might be a therapeutic target
to slow PD progression.
Nrf2 regulates the expression of a battery of genes involved
in defense against oxidant and xenobiotic compounds that
constitute the so-called phase II response (2). These genes code
heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreduc-
tase 1 (NQO1), glutathione reductase, and the catalytic and
modulator subunits of c- glutamyl cysteine ligase (GCL-C and
GCL-M, respectively) among many others (13, 15–17). In
Supplementary Figure S1 (Supplementary Data are available
online at www.liebertonline.com/ars), we suggest a role for
some Nrf2-regulated genes in elimination of hydrogen per-
oxide and DA-quinones in dopaminergic neurons.
Several important findings connect Nrf2 with PD. Nrf2
activity declines with age, which is the main risk factor for PD.
Interestingly, the transcriptional activity of Nrf2 can be re-
stored pharmacologically in old animals (30). In nigral do-
paminergic neurons, Nrf2 is located at the cytosol, whereas in
age-matched patients with PD, Nrf2 is found at the nucleus,
suggesting an attempt to reduce oxidative stress through
Nrf2-dependent transcription of antioxidant enzymes (22).
Finally, a functional haplotype in the Nrf2 gene promoter,
which confers high transcriptional activity (20), has been re-
ported to be protective in two groups of European patients
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with PD (32). Concerning animal models, Nrf2-deficient
mice are more susceptible to 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced neurodegeneration and
inflammation (1, 4, 24).
In the absence of stimuli, Nrf2 is located at the cytosol,
bound to a protein, Keap1, that targets it for degradation
through the ubiquitin-proteasome pathway and, therefore, it
has a very short half-life. Several drugs alter the Nrf2/Keap1
complex through adduct formation with specific Keap1 cyste-
ines, leading to Nrf2 stabilization and translocation to the
nucleus where it activates phase II gene transcription (16). In
the present study, we chose sulforaphane (SFN) to target Nrf2
in the basal ganglia. SFN is an isothiocyanate found in crucif-
erous vegetables such as broccoli that has gained attention as a
chemopreventative (34) and anti-inflammatory compound (11)
mostly in in vitro experiments or in peripheral tissues.
Our results indicate that indeed SFN crosses the blood
brain barrier, induces an Nrf2-dependent phase II response in
the basal ganglia, and protects against nigral dopaminergic
cell death, astrogliosis, and microgliosis in the MPTP mouse
model of PD.
Materials and Methods
Animals and treatments
All animal protocols were approved by the Ethical Com-
mittee for Research of the Universidad Auto´noma de Madrid
following institutional, Spanish, and European guidelines
(Boletı´n Oficial del Estado of 18 March 1988; and 86/609/EEC,
2003/65/EC European Council Directives). Nrf2-knockout
mice and their wild-type littermates were obtained thanks to
the courtesy of Dr. Masayuki Yamamoto (Tohoku University
Graduate School of Medicine, Sendai, Japan) (12). MPTP
(Sigma-Aldrich, St. Louis, MO) and SFN (LKT Laboratories,
St. Paul, MN) were prepared in saline solution just before use.
Animals were anesthetized with 8 mg/kg ketamine and
1.2 mg/kg xylazine, and some of them were perfused with 4%
paraformaldehyde. The nonperfused brains were dissected,
and two regions corresponding to striatum (STR) and ventral
midbrain (VMB) were rapidly frozen at - 80C for RNA,
protein, and/or DA measurements.
Analysis of mRNA levels by quantitative
polymerase chain reaction
Total RNA was extracted from STR using TRIzol reagent
according to the manufacturer’s instructions (Invitrogen,
Paisley, United Kingdom). One micrograms of RNA from the
different treatments was reverse-transcribed in 20lL using
High Capacity RNA-to-cDNA Kit (Applied Biosystems,
Carlsbad, CA) according to manufacturer’s instructions. Poly-
merase chain reactions (PCRs) and primers have been previ-
ously described (11). All PCRs were performed in triplicate.
Determination of DA, DOPAC, SFN, and MPP +
by high-performance liquid chromatography
For high-performance liquid chromatography (HPLC)
analysis of DA and its major intraneuronal degradation
product, dihydroxyphenylacetic acid (DOPAC), STRs were
homogenized in 50 volumes of ice-cold 0.2 N perchloric acid
containing 0.2 mM sodium disulfide and 0.45 mM EDTA.
Dihydroxybenzylamine was added as an internal standard.
HPLCs were performed as previously described (9). For
HPLC determination of SFN, STR and VMB were dissected
and rapidly frozen at - 80C. Samples were sonicated in 10
volumes (w/v) of methanol and analyzed as previously de-
scribed (11). For determination of 1-methyl-4-phenylpyr-
idinium (MPP + ) levels, STR and VMB were dissected and
rapidly frozen at - 80C. Samples were sonicated in 10 vol-
umes (w/v) of 5% trichloroacetic acid containing 10 lg/mL of
4-phenylpyridine (Sigma-Aldrich) as internal standard and
analyzed as previously described (23, 25).
Immunohistochemistry
Animals were perfused, brains fixed, and 30-lm-thick cor-
onal sections obtained as previously described (24). Sections
were rinsed in 100 mM Tris–HCl, pH 7.6, and 225 mM NaCl
(TBS). Tissue peroxidase was inactivated by incubating in 10%
methanol and 3% hydrogen peroxide in Tris-buffered saline
(TBS) for 30 min. After three washes in TBS, sections were in-
cubated for 3 h in blocking solution (10% goat serum, 0.3% Triton
X-100 in TBS) and then for 24 h at 4C with mouse anti-tyrosine
hydroxylase (TH) (1:500; Millipore, Billerica, MA), rabbit anti-
glial fibrillary acidic protein (GFAP) (1:500; Dako, Glostrup,
Denkmark), or rabbit anti-Iba1 (1:500; Wako Chemicals, Rich-
mond, VA). Sections were rinsed in TBS, then incubated with
rabbit anti-mouse or anti-rabbit secondary antibodies at 1/1000
dilution for 1 h at room temperature (Vector Labs, Burlingame,
CA). Sections were subsequently developed by avidin-biotin
peroxidase complex system following manufacturer’s instruc-
tions (ABC Kit, Vector Labs). Control sections were treated with
the same protocol but omitting the primary antibody.
Immunofluorescence
Parallel series of 30-lm-thick coronal sections were rinsed
in phosphate-buffered saline (PBS) and incubated for 1 h in
blocking solution. Double immunofluorescence was per-
formed by incubating the sections for 24 h at 4C with the
following primary antibodies: mouse anti-TH (1:500; Milli-
pore), rabbit anti-GFAP (1:500; Dako), or rabbit anti-Iba1
(1:500; Wako Chemicals), diluted in PBS containing 0.5% goat
serum and 0.3% Triton X-100. Sections were washed thrice in
PBS and then incubated with secondary antibodies: Alexa
Fluor 488 anti-mouse or Alexa Fluor 546 anti-rabbit (Mole-
cular Probes, Carlsbad, CA) at 1:500 dilution for 1 h. Control
sections were treated with the same protocol but omitting the
primary antibody. Double immunofluorescence with rabbit
antibodies for HO-1 (1:100; Millipore) and either GFAP (1:500;
Dako) or Iba1 (1:500; Wako Chemicals) was performed with
the use of tyramide amplification system according to the
manufacturer’s protocol (Perkin Elmer, Boston, MA). Sections
were first incubated in 10% normal goat serum in PBS for 1 h
at room temperature, followed by incubation with the poly-
clonal rabbit HO-1 antibody in 0.5% goat serum and 0.2%
Triton X-100 in PBS overnight. Subsequently, the sections
were incubated with biotinylated goat anti-rabbit IgG for 1 h,
with avidin-biotin complex (ABC; Vector Labs) for 1 h, bioti-
nylated tyramide for 10 min and then ExtrAvidin-FITC (Sig-
ma-Aldrich) (1:500, 2 h). Second primary antibody was Alexa
Fluor 546-conjugated anti-rabbit (Molecular Probes) (1:250,
1 h). Control sections were treated with the same protocol but
omitting the primary antibody or tyramide amplification step.
Fluorescence images were captured in a Leica DMIRE2TCS
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SP2 confocal microscope (Nussloch, Germany). The lasers
used were Ar 488 nm for green fluorescence and Ar/HeNe
543 nm for red fluorescence.
Stereological quantification
Cell counts were performed every four sections (30lm thick)
through the SN using Stereo Investigator Software (Micro-
Brightfield, Colchester, VT) attached to an E800 Nikon micro-
scope (Nikon, Montreal, QC, Canada). SN, excluding ventral
tegmental area, was delineated in low magnification (5· ob-
jective), and a point grid was overlaid onto each section. For
Nissl staining, TH-stained sections were rehydrated in xylene
and graded alcohols and incubated in Nissl’s solution (0.1%
Cresyl Violet [Sigma-Aldrich], 2.5 mL acetic acid 10%) at room
temperature for 15 min. Sections were rinsed in deionized water
for 5 min, dehydrated in graded alcohols, cleared in xylene,
and coverslipped. Stained cells were counted by the optical
FIG. 1. Sulforaphane (SFN)
crosses the blood–brain bar-
rier and upregulates NF-E2-
related factor 2 (Nrf2), and
neither SFN treatment nor
Nrf2 deficiencies alters 1-
methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP)
conversion. (A, B) High-per-
formance liquid chromatog-
raphy determination of SFN
in striatum (STR) and ventral
midbrain (VMB), respec-
tively, after intraperitoneal
injection of 50 mg/kg SFN.
(C) Striatal immunoblots
showing a time-course in-
duction of Nrf2 by SFN in
STR of Nrf2 +/ + but not
Nrf2 -/ - mice. Lane C is a
positive control for Nrf2 im-
munodetection using
HEK293T cells transfected
with expression vector for
mouse Nrf2. Upper panel:
Nrf2 protein levels. Lower
panel: b-actin protein levels.
(D) densitometric quantifica-
tion of Nrf2 protein levels
from representative immu-
noblots after normalization
by b-actin in Nrf2 +/ + mice.
Values represent mean– SD
of three to five mice per time
point. Asterisks denote sig-
nificant differences between
treatments with p < 0.05. (E)
Nrf2 +/ + and Nrf2 -/- mice
were treated with saline or
SFN and sacrificed after 16 h.
STR protein extracts were
immunoblotted as indicated:
Upper panel, anti- dopamine
transporter (DAT) antibody;
middle panel, anti-monoamine
oxidase-B (MAO-B) anti-
body; lower panel, anti-b-actin
antibody showing similar
load of protein per lane. (F)
Mice were injected i.p. with
saline or SFN, and after 16 h
they were injected again with MPTP at a dose of 30 mg/kg. 1-methyl-4-phenylpyridinium (MPP+ ) in STR was determined at
30 and 60 min after MPTP injection. (G) Comparison of MPP + levels in STR and VMB from Nrf2 +/ + and Nrf2 -/- mice
60 min after injection of MPTP (30 mg/kg). Values represent mean – SD of three to five mice per group and per time point.
Differences are not statistically significant.
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fractionator method at high magnification (63· objective, N.A.
1.25) distinguishing between TH-positive (TH and Nissl posi-
tive) and TH-negative (Nissl positive). TH- and Nissl-stained
neurons were counted only when their nuclei were optimally
visualized within one focal plane. Nissl-stained neurons were
differentiated from non-neuronal cells by clearly defined nu-
cleus, cytoplasm, and a prominent nucleolus. Total numbers of
neurons in the SN were calculated as described in (33).
Immunoblotting
STR and VMB were removed rapidly and homogenized on
ice with lysis buffer (25 mM Tris-HCl, pH 7.6; 150 mM NaCl;
1 mM EGTA; 20 mM NaF; 1 mM sodium pyrophosphate;
1 mM Na3VO4; 1% Nonidet P-40 [Sigma-Aldrich]; 1% sodium
deoxycholate; 0.1% sodium dodecyl sulfate [SDS]; 1 mM
phenyl methyl sulfonyl fluoride, and 1 lg/mL leupeptin).
Protein extracts were cleared by centrifugation, and 30 lg
protein were resolved by SDS-PAGE and transferred to im-
mobilon-P membranes (Millipore). Blots were analyzed
with the appropriate antibodies: anti-Nrf2 (1:2000, gift of
Dr John D. Hayes, University of Dundee, Dundee, Scotland), a
anti-dopamine transporter (DAT) (1:500; Millipore), anti-
monoamine oxidase-B (MAO-B) (1:500; Santa Cruz Bio-
technology), anti-TH (1:2000; Millipore), anti-GFAP (1:2000,
Dako), anti-HO-1 (1:2000; Millipore), anti-NQO1 (1:500;
Abcam, Cambridge, United Kingdom), anti-GCL-C (gift of
Dr Terrance Kavanagh, University of Washington, USA), anti-
IL-6 (1:1000; Abcam), anti-TNF-a (1:1000; Abcam), and anti-
b-actin (1:1000, Santa Cruz Biotechnology). Appropriate per-
oxidase-conjugated secondary antibodies (1:10,000) were
used to detect the proteins of interest by enhanced chemilu-
minescence (Advanced ECL; GE Healthcare, Waukesha, WI).
Quantification and statistics
Density of TH-positive fibers in the STR, HO-1, and GFAP
fluorescence and band intensities corresponding to immuno-
blots were quantified using the MCID software (MCID,
Cambridge, United Kingdom). Results are expressed as
FIG. 2. SFN treatment activates the phase
II response in STR and VMB. Nrf2 +/+ and
Nrf2 -/ - mice were treated with SFN and
analyzed after 16 h. (A, C) Immunoblots
showing induction of heme oxygenase-1
(HO-1) and NAD(P)H quinona oxidoreduc-
tase 1 (NQO1) in STR and VMB respectively.
Upper panels, HO-1 protein levels; middle
panels, NQO1 protein levels; lower panels, b-
actin protein levels. (B, D) Densitometric
quantifications from representative immu-
noblots, normalized with b-actin, of STR and
VMB, respectively. Values represent mean –
SD of three to five mice per group. Asterisks
denote significant differences between treat-
ments with p< 0.05. (E) Double immunoflu-
orescence of wild-type mice treated with
SFN or vehicle according to the protocol
depicted in Figure 3A. Sections from day 6
were stained with anti-HO-1 antibody (green)
and anti-glial fibrillary acidic protein (GFAP)
antibody (red). Pictures show representative
astrocytes within the coronal sections of STR.
(F) Quantification of HO-1 expressing astro-
cytes. GFAP-stained cells were classified in
the green channel as nonstained and HO-1-
stained astrocytes. Background fluorescence
was taken as that of surrounding tissue as
determined with the MCID program. Values
indicate percentage of astrocytes expressing
HO-1 – SEM from 470 astrocytes (two mice)
in saline-treated and 450 astrocytes (three
mice) in SFN-treated mice. Asterisk denotes
significant differences between treatments
with p < 0.05. (To see this illustration in color
the reader is referred to the web version of
this article at www.liebertonline.com/ars).
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mean – SD. One-way ANOVA followed by Bonferroni’s post
hoc test or unpaired Student’s t test was used to evaluate the
statistical significance between investigated groups.
Results
SFN crosses the blood–brain barrier and upregulates
Nrf2 in basal ganglia
Animals were i.p. injected either with saline or with SFN
(50 mg/kg), and SFN levels were determined at the indicated
time points in VMB and STR by HPLC. As shown in Figure
1A and B, SFN was detected at both locations with maximal
levels after 15 min and was still present after 60 min. Then,
we analyzed whether the amount of SFN that reaches the
brain is sufficient to activate Nrf2. Striatal protein lysates
of SFN-treated Nrf2 + / + and Nrf2 - / - mice were im-
munoblotted with anti-Nrf2 antibody. As shown in Figure
1C and D, already at 1 h after i.p. injection, SFN provoked
about sixfold increase in Nrf2 protein levels in the STR of
Nrf2 + / + mice and its expression gradually decreased
reaching basal levels within 4 h. Importantly, Nrf2 - / - mice
submitted to the same protocol exhibited neither basal nor
FIG. 3. Protocol for induction of a phase II response in STR and VMB. (A) Combined protocol of SFN and MPTP
delivery. SFN and MPTP were given i.p. at doses of 50 and 30 mg/kg, respectively, at the indicated days (filled circles for
MPTP injections and empty circles for SFN injections). Animals were sacrificed at days 0, 3, and 6. (B, C) Immunoblots of STR
and VMB protein extracts, respectively, blotted with anti-HO-1, anti-NQO1, anti-c-glutamyl cysteine ligase-catalytic subunit
(GCL-C), anti-c-glutamyl cysteine ligase-modulator subunit (GCL-M), and anti-b-actin antibodies. (D, E, F, G) Densitometric
quantification from representative immunoblots of STR lysates after normalization with b-actin. (H, I, J, K) Densitometric
quantification from representative immunoblots of VMB lysates after normalization with b-actin. Values represent mean– SD
of three to five mice per group and per time point. Asterisks denote significant differences between treatments with p< 0.05.
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SFN-induced Nrf2 expression (Fig. 1C). Therefore, we con-
clude that SFN crosses the blood brain barrier and upregu-
lates striatal Nrf2.
Next, we determined whether Nrf2 deficiency or SFN
treatment might interfere with the normal in vivo conversion
of MPTP to its active principle, MPP + (Fig. 1E). We analyzed
protein levels of MAO-B, an enzyme that converts MPTP to
MPP + , and DAT, which mediates MPP + uptake by nigral
dopaminergic neurons. Nrf2 +/ + and Nrf2 -/ - mice were in-
jected i.p. either with saline or with 50 mg/kg SFN; and
FIG. 4. SFN protects against MPTP-induced neurotoxicity in the SN of Nrf21/1 but not Nrf2 -/ - mice. Mice were
submitted to the combined protocol of SFN and MPTP delivery. (A) Immunohistochemistry with anti-tyrosine hydroxylase
(TH) antibody in Nrf2 +/ + mice in 30lm-thick coronal sections of VMB. Rectangles indicate SN. (B) Stereological quantifi-
cation of TH-immunoreactive neurons in SN of Nrf2 +/ + and Nrf2 -/ - mice. (C) Stereological quantification of Nissl-positive
neurons in SN of Nrf2 +/+ and Nrf2 -/ - mice. Values represent mean – SD of three to five mice per group and per time point.
Asterisks denote significant differences between treatments with p< 0.05. (To see this illustration in color the reader is referred
to the web version of this article at www.liebertonline.com/ars).
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striatal protein lysates were analyzed after 16 h. MAO-B and
DAT levels were similar among genotypes and treatments. In
additional experiments, we analyzed the conversion of MPTP
to MPP + by HPLC (Fig. 1F, G). Striatal MPP+ levels were very
similar in saline- and SFN-treated mice at 30 and 60 min after
injection of 30 mg/kg MPTP. Moreover, STR or VMB levels of
MPP + were also similar in Nrf2 +/ + and Nrf2 -/ - mice at
30 min after MPTP injection. These results indicate that nei-
ther Nrf2 deficiency nor SFN treatment interfere with the
MPTP conversion to MPP + .
FIG. 5. SFN protects against MPTP-induced neurotoxicity in STR of Nrf21/1 but not Nrf2 -/- mice. Animals
were submitted to the combined protocol of SFN and MPTP delivery. (A) Immunohistochemistry with anti-TH antibody.
Pictures show 30 lm-thick coronal sections of STR of Nrf2 +/ + mice. (B) Densitometric quantification of TH-positive fibers in
Nrf2 +/ + and Nrf2 -/ - mice. (C, D) High-performance liquid chromatography determination of dopamine (DA) and dihy-
droxyphenylacetic acid (DOPAC), respectively, in STR of Nrf2 +/+ mice. (E) Immunoblots of striatal protein extracts from
Nrf2 +/ + and Nrf2 -/ - mice blotted with anti-TH and anti-b-actin antibodies. (F) Densitometric quantification from repre-
sentative immunoblots after normalization to b-actin. Values represent mean– SD of three to five mice per group and per
time point. Asterisks denote significant differences between treatments with p < 0.05. (To see this illustration in color the
reader is referred to the web version of this article at www.liebertonline.com/ars).
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SFN activates the phase II response in STR
To determine the relevance of Nrf2 activation, we analyzed
the protein levels of two typical Nrf2-regulated phase II en-
zymes, HO-1 and NQO1, in Nrf2 +/ + and Nrf2 -/- mice at
16 h after SFN administration. SFN was able to induce about
twofold increase of HO-1 and NQO1 in STR (Fig. 2A, B) and
VMB (Fig. 2C, D) of Nrf2 +/ + mice but not in their Nrf2 -/-
littermates. Therefore, SFN activates the antioxidant response
in STR and VMB in an Nrf2-dependent manner.
To identify the cell types that might be responding to SFN,
we performed double immunofluorescence for HO-1 and the
markers tyrosine hydroxylase (TH) (dopaminergic neurons),
tomato lectin (endothelial cells), Iba-1(microglia), or GFAP
(astrocytes). As shown in Supplementary Figure S2, endo-
thelial cells and microglia had very low levels of HO-1 that
were not substantially changed by SFN. Dopaminergic neu-
rons exhibited a diversified pattern of TH staining and HO-1
staining that was not altered by SFN. Finally, as shown also in
Figure 2E and, some astrocytes from saline inoculated mice
exhibited a very weak HO-1 staining that was increased in the
SFN-treated mice. These results point the astrocytes as the
main SFN responsive cells in the basal ganglia.
Design of a protocol for sustained induction of phase II
enzymes by SFN in the basal ganglia
Several schedules and doses of SFN were tested to achieve
a steady increase in the levels of phase II enzymes in STR and
VMB (data not shown). Since SFN did not show evidence of
toxicity even at the very high dose of 50 mg/kg, for the
purpose of this study we used the protocol depicted in Fig-
ure 3A. This protocol consisted of two i.p. injections of SFN
(50 mg/kg, 8-h interval, day - 1), which, on the next day
(day 0), led to increased HO-1 and NQO1 protein levels (Fig.
2). We have previously observed that such upregulated HO-
1 protein levels remain elevated for at least 48 h (11).
Therefore, the reinforcement doses of SFN were adminis-
tered at days 1, 3, and 5. MPTP (30 mg/kg) was injected i.p.
for 5 consecutive days starting at day 0. Under these condi-
tions, SFN elicited about twofold increase in the expression
of STR and VMB phase II enzymes HO-1, NQO1, GCL-M,
FIG. 6. SFN prevents against MPTP-induced astrogliosis in VMB. Wild-type mice were submitted to the combined
protocol of SFN and MPTP delivery. (A, B) Immunohistochemistry with anti-GFAP antibody. Pictures show coronal sections
of VMB. The outlined area indicates the substantia nigra pars compacta (SNc) located above the substantia nigra pars
reticulata (SNr) and cerebral peduncle (CP). (C) Double immunofluorescence with anti-TH (green) and anti-GFAP (red)
antibodies from the SN region at day 6. Pictures are representative of three to five animals per group and per time point. (To
see this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).
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and GCL-C at days 3 and 6, compared with control untreated
animals (Fig. 3).
SFN is neuroprotective against MPTP-induced
dopaminergic neuron damage
Mice were submitted to MPTP or SFN according to the
protocol shown in Figure 3A and 30 lm-thick sections from
VMB were used for TH-immunohistochemistry. MPTP-trea-
ted mice exhibited a substantial loss of TH immunoreactivity
in VMB that was perceptible already at day 3 and even more
exaggerated at day 6 (Fig. 4A). Concurrently, stereological
count of TH-positive and Nissl-positive cells within the area
outlined in Figure 4A indicated a reduction of dopaminergic
neurons of about 30% at day 3 and about 60% at day 6 in
comparison to the saline-treated animals (Fig. 4B, C). Inter-
estingly, SFN partially rescued both MPTP-induced loss of
TH-staining and dopaminergic neuron abundance, particu-
larly at day 6. By contrast, SFN did not protect significantly
against dopaminergic neuron loss in the Nrf2-deficient mice.
Striatal dopaminergic fibers were also protected by SFN in
wild-type mice (Fig. 5A, B). Striatal DA and DOPAC levels
were analyzed by HPLC (Fig. 5C, D). The MPTP lesion re-
moved nearly 80% of striatal DA and DOPAC. By contrast,
SFN led to a modest but significant rescue of both DA and
DOPAC levels.
To further exclude off-target effects of SFN in STR, we
submitted Nrf2 -/ - mice and Nrf2 +/ + littermates to the
combined SFN/MPTP protocol. As for neuron bodies in VMB
(Fig. 4B, C), TH-stained fibers were not protected by SFN in
the Nrf2-knockout mice (Fig. 5B). Also, we analyzed TH
protein levels by immunoblot (Fig. 5E, F). MPTP elicited a 68%
and 82% reduction of TH in Nrf2 +/+ and Nrf2 -/ - mice, re-
spectively, but more importantly, although SFN rescued TH
protein levels to more than 50% in Nrf2 +/+ mice, it did not
have a any consequence on the Nrf2 -/ - mice. Therefore,
these results indicate that the protective effect of SFN against
MPTP-induced nigrostriatal damage is provided by Nrf2 and
we focused the rest of this study on wild-type mice.
SFN attenuates MPTP-induced astrogliosis
One of the hallmarks of the inflammatory response to
MPTP is the increased number of astrocytes within the ni-
grostriatal tract, STR and SN. Therefore, astrogliosis was
analyzed in coronal sections of VMB immunostained with
anti-GFAP antibody (Fig. 6A, B). We observed radial astroglia
in the brain peduncles and there was very little immunore-
activity in the outlined region of substantia nigra of saline-
and SFN-treated mice. As expected, in MPTP-treated mice we
detected an increased number of astrocytes in this site (Fig.
6A). GFAP immunoreactivity after MPTP and SFN treatment
FIG. 7. SFN reduces the MPTP-induced astrogliosis in STR. Wild-type mice were submitted to the combined protocol of
SFN and MPTP delivery. (A, B) Immunohistochemistry with anti-GFAP antibody. Pictures show coronal sections of STR.
Insets show high-magnification STR fields with resting (Saline day 6) and activated (MPTP day 6) astrorytes. (C) Double
immunofluorescence with anti-TH (green) and anti-GFAP (red) antibodies from STR at day 6. Pictures are representative of
three to five animals per group and per time point. (To see this illustration in color the reader is referred to the web version of
this article at www.liebertonline.com/ars).
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was lower when compared with MPTP-injected animals at
days 3 and 6 (Fig. 6B). To further confirm this observation, we
performed double immunofluorescence staining with anti-TH
and anti-GFAP antibodies in VMB sections from day 6 (Fig.
6C). In saline- and SFN-treated animals, the SN was occupied
by many TH-positive neurons and very few astrocytes. By
contrast, in MPTP-treated mice we found lower abundance of
TH-positive neurons and many astrocytes forming the glial
scar. Interestingly, in animals submitted to both SFN and
MPTP injections, we found an intermediate pattern with more
dopaminergic neurons and fewer astrocytes.
The MPTP-induced astrogliosis in STR was also attenuated
by SFN (Fig. 7A, B). Immunohistochemical staining with anti-
GFAP antibodies revealed just a few astrocytes in STR of saline
or SFN-treated animals. These astrocytes exhibited a small
body and very thin branches, evidencing a resting state (Fig.
7A, B, insets). By contrast, STR from MPTP-treated mice at days
3 and 6 was crowded with astrocytes that at higher magnifi-
cation demonstrated thick bodies and branches, indicating
their activation state (Fig. 7A). Animals submitted to both SFN
and MPTP injections presented also high abundance of STR
astrocytes, but they were not as abundant as in the MPTP-
treated mice (Fig. 7B). Further confirmation of the inhibitory
effect of SFN on STR astrogliosis was obtained by double im-
munofluorescence of sections from day 6 stained with anti-TH
and anti-GFAP antibodies (Fig. 7C). Saline- and SFN-treated
animals exhibited a reticulated anti-TH staining pattern, cor-
responding to dopaminergic fibers, and a few scattered astro-
cytes with resting morphology. As expected, MPTP-lesioned
mice exhibited weak immunolabeling for TH-positive nerve
fibers and a larger number of astrocytes. Finally, mice sub-
mitted to both MPTP and SFN presented an intermediate
pattern, with more TH fibers and fewer astrocytes than MPTP-
treated animals. Overall, these results indicate that Nrf2 acti-
vation by SFN decreases astrogliosis in response to MPTP.
SFN attenuates MPTP-induced microgliosis
We examined the levels of microgliosis using Iba-1 immu-
noreactivity (Fig. 8A, B). In saline- and SFN-treated mice, we
FIG. 8. SFN prevents against MPTP-induced microgliosis in VMB. Wild-type mice were submitted to the combined
protocol of SFN and MPTP delivery. (A, B) Immunohistochemistry with anti-Iba-1 antibody. Pictures show coronal sections
of VMB. The outlined area indicates the substantia nigra pars compacta (SNc) located above the substantia nigra pars
reticulata (SNr) and cerebral peduncle (CP). (C) Double immunofluorescence with anti-TH (green) and anti-Iba-1 (red) anti-
bodies from the SN region at day 6. Pictures are representative of three to five animals per group and per time point. (To see
this illustration in color the reader is referred to the web version of this article at www.liebertonline.com/ars).
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could barely detect microglia in the outlined area of VMB
corresponding to SN. By contrast, MPTP-treated mice
exhibited strong increase in Iba-1 immunoreactive cells at days
3 and 6. In mice submitted to both MPTP and SFN injections,
microglial activation was more moderate, particularly at day 6.
Further evidence for microglial activation in the SN was ob-
tained by double immunofluorescence of VMB sections stained
with anti-TH and anti-Iba1 antibodies (Fig. 8C). Saline- and
SFN-treated mice exhibited a similarly high abundance of TH-
positive dopaminergic neurons and very few microglial cells.
MPTP treatment led to dopaminergic neurons loss and strong
microgliosis. Finally, animals submitted to combined MPTP
and SFN delivery exhibited an intermediate pattern with more
dopaminergic neurons and fewer microglia.
Similar analysis was performed in STR (Fig. 9A, B). At high
magnification, we observed just a few microglial cells of either
saline- or SFN-treated mice. Exposure to MPTP led to a mild
increase in Iba-1 expressing microglia and this tendency was
partially blocked by SFN. Again, these results were further
corroborated by double immunofluorescence in STR sections
stained with anti-TH and anti-Iba1 antibodies (Fig. 9C). The
reduction in dopaminergic fibers induced by MPTP was as-
sociated with an increase in Iba1-positive microglia. By con-
trast, in the presence of SFN there was a lower reduction of
dopaminergic fibers and a lower microgliosis. These results
indicate that the loss of nigrostriatal DA neurons in response
to MPTP is accompanied by increased microgliosis and that
this situation is partially reversed by SFN.
SFN attenuates the pro-inflammatory
response caused by MPTP
One of the consequences of induced gliosis is the secretion
of pro-inflammatory mediators such as interleukins among
others in the brain parenchyma. We examined the levels of
two classical pro-inflammatory mediators, interleukin-6 (IL-6)
and tumor necrosis factor-a (TNF-a), in STR (Fig. 10A, C).
Messenger RNA analysis by q quantitative PCR revealed that
both cytokines are upregulated on MPTP exposure, an effect
partially inhibited after SNF treatment. Similarly, striatal
protein extracts from MPTP-injected mice immunobloted
with anti-IL-6 and anti-TNF-a antibodies exhibit increased
levels of both cytokines (Fig. 10B, D). Again, SFN attenuated
the MPTP-induced increase in IL-6 and TNF-a proteins. Taken
together, these results suggest that SFN attenuates the MPTP-
induced production of pro-inflammatory mediators in basal
ganglia.
Discussion
In this study, we activated pharmacologically the tran-
scription factor Nrf2 in the brain to determine its role in
neuroprotection and modulation of neuroinflammation in an
experimental model of PD. For this purpose, we used the
potent Nrf2 inducer SFN (6, 8, 18). Given i.p. at a dose of
50 mg/kg, SFN was found in STR and VMB, two locations
involved in the motor pathology of PD. This concentration
was selected after trial and error of several other conditions
and is compatible with low mortality of mice submitted to the
sub-acute model of MPTP (30 mg/kg MPTP per i.p. injection,
5 consecutive days).
SFN levels detected in the STR were sufficient to increase
striatal Nrf2 protein for 2 h. Moreover, two i.p. injections of
SFN (50 mg/kg) resulted in upregulation of the phase II
enzymes such as HO-1 and NQO1 by about two- to three-
fold. This low over-expression was probably an advantage of
this protocol, because very high phase II enzymes levels may
have detrimental effects (19). Thus, an increase on HO-1 of
this magnitude in transgenic mice was neuroprotective in a
model of glutamate induced excitotoxicity (3), whereas high
HO-1 over-expression promoted oxidative mitochondrial
damage in rat astrocytes by a mechanism that is probably
mediated by ferrous iron (29). Of note, wild-type and HO-1-
deficient mice exhibit similar iron levels in VMB when they
are treated with MPTP (9). Therefore, iron accumulation in
the parkinsonian brain may be more associated with iron
clearance mechanisms such as the divalent metal trans-
porter, ferritin-mediated cellular export, transferring se-
questration, or with iron supply mechanisms by lactoferrin
(27, 28) rather than with heme degradation by HO-1. Con-
sequently, pharmacological targeting of Nrf2 may be a fea-
sible therapy excluding the concern about HO-1 mediated
toxicity. Other Nrf2-regulated genes might be relevant in PD
therapy including NQO1 and enzymes related to glutathione
synthesis and usage. Supplementary Figure S1 shows the
role of some phase II enzymes in oxidant protection of do-
paminergic neurons.
All nerve cells analyzed, including microglia, astroglia,
endothelium, and neurons, have a functional Nrf2-dependent
phase II response in vitro (data not shown; (7, 11, 31, 35).
Therefore, we rationed that all these cell types would respond
similarly to SFN induction in vivo. Also, since the increase in
FIG. 9. SFN reduces the MPTP-induced microgliosis in
STR. Wild-type mice were submitted to the combined pro-
tocol of SFN and MPTP delivery. (A, B) Immunohisto-
chemistry with anti-Iba-1 antibody. Pictures show coronal
sections of STR. (C) Double immunofluorescence with anti-
TH (green) and anti-Iba-1 (red) antibodies from STR at day 6.
Pictures are representative of three to five animals per group
and per time point. (To see this illustration in color the reader
is referred to the web version of this article at www
.liebertonline.com/ars).
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phase II enzymes HO-1 and NQO1 was modest in immuno-
blots, we did not expect to see a clear increase in HO-1 protein
levels associated with specific cell types. However, we found
that HO-1 was upregulated in STR astrocytes after SFN
treatment, suggesting that this cell type is more sensitive to
phase II induction. Therefore, although it is possible that a low
level of phase II upregulation in all nerve cell types might
participate in brain modulation, at least the astrocytes should
have a relevant role either by increasing their nurturing effect
toward neurons or as immune modulators. This observation
is in line with another study reporting that Nrf2 expression
restricted to astrocytes is sufficient to protect against MPTP-
induced toxicity (4).
Several genomics analyses have been conducted for the
past 10 years to identify Nrf2-regulated genes, and so far there
is no evidence that those involved in MPTP metabolism might
be targets of Nrf2. Concordantly, wild-type and the Nrf2-
knockout mice as well as saline- and SFN-treated mice ex-
hibited similar levels of MAO-B and DAT. Further, striatal
MPP + levels did not differ between Nrf2 +/ + mice and
Nrf2 -/- littermates or between saline- and SFN-treated mice.
These results exclude possible effects of Nrf2 and SFN that
might be related to MPTP biotransformation or MPP + avail-
ability rather than with a direct effect on brain protection.
Although Keap1/Nrf2 appear to be the preferred molecular
target of SFN, its capacity to form adducts with other cellular
macromolecules cannot be excluded. In fact, SFN has been
reported to inhibit histone deacetylase (5) and participate in
apoptosis and cell cycle arrest (26). Nevertheless, in this study
we found that the SFN did not protect against MPTP-induced
loss of TH immunoreactivity in the Nrf2-knockout mice,
therefore, excluding off-target effects.
Nrf2 activation by SFN attenuated the nigrostriatal neu-
rodegeneration induced by MPTP. Thus, the number of do-
paminergic neurons (Nissl and TH positive) in the SN that
survived MPTP was about 50% in the presence of SFN
compared with MPTP-treated groups. Further, the density of
TH-positive fibers in STR was protected by 20% compared
with MPTP-treated mice. Striatal DA and DOPAC levels
were also partially rescued by SFN but to a lesser, yet sig-
nificant, extent than dopaminergic neuron loss. Although we
do not have a convincing explanation, this small discrepancy
may be related to compensatory mechanisms of the surviv-
ing neurons.
This preclinical study provides strong evidence to endorse
a brain protective therapy in patients with PD by pharma-
cological targeting of the transcription factor Nrf2. Since SFN
is a natural compound of many diets and because it is now
being used in clinical trials for other pathologies (18, 21), it
should be reasonable to use it as neuroprotective therapy
together with DA replacement therapy. Issues to be solved
include more specific pharmacokinetic and pharmacody-
namic studies in humans and improvement of the route of
administration.
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FIG. 10. SFN reduces the pro-inflammatory response
induced by MPTP in STR. Wild-type mice were submit-
ted to the combined protocol of SFN and MPTP delivery.
(A) IL-6 mRNA levels determined by quantitative poly-
merase chain reaction. (B) Immunoblot of striatal protein
extracts blotted with anti-IL-6 antibody. (C) TNF-a mRNA
levels determined by quantitative polymerase chain reac-
tion. (D) Immunoblot of striatal protein extracts blotted
with anti-TNF-a antibody. Values represent mean – SD of
three to five mice per group and per time point. Asterisks
denote significant differences between treatments with
p < 0.05.
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Abbreviations Used
DA¼dopamine
DAT¼dopamine transporter
DOPAC¼dihydroxyphenylacetic acid
GCL-C¼ c-glutamyl cysteine ligase-catalytic
subunit
GCL-M¼ c-glutamyl cysteine ligase-modulator
subunit
GFAP¼ glial fibrillary acidic protein
HO-1¼heme oxygenase-1
HPLC¼high-performance liquid
chromatography
i.p¼ intraperitoneal
MAO-B¼monoamine oxidase-B
MPP+¼ 1-methyl-4-phenylpyridinium
MPTP¼ 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine
NQO1¼NAD(P)H quinona oxidoreductase 1
Nrf2¼NF-E2-related factor 2
Nrf2= and Nrf2+=+¼C57BL/6 mice knockout for Nrf2 or
wild type littermates, respectively
PBS¼phosphate-buffered saline
PD¼Parkinson’s disease
SFN¼ sulforaphane
SDS-PAGE¼ sodium dodecyl sulfate–
polyacrylamide gel electrophoresis
TBS¼Tris-buffered saline
TH¼ tyrosine hydroxylase
STR¼ striatum
VMB¼ventral midbrain
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